Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2016-11-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
第五届董事会第九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolution passed at the company's fifth board of directors' ninth meeting. It details the approval of a proposal to extend the suspension of trading due to a major asset restructuring and mentions the intention to disclose a restructuring plan by a future date. The document includes voting results and references related announcements published elsewhere. It does not contain full financial statements or detailed financial analysis, nor is it a transcript, report, or presentation. It is an official announcement related to board decisions, specifically about a major asset restructuring and trading suspension extension. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2016-11-25 Chinese
关于重大资产重组停牌进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the progress of a major asset restructuring involving the issuance of shares to purchase assets. It includes information about the transaction parties, the nature of the transaction, the assets involved, and the company's commitments during the suspension period. The document is titled as a progress announcement related to a major asset restructuring and includes multiple references to suspension and resumption of trading due to this restructuring. It does not contain financial statements or detailed financial performance data but rather updates on the status of the transaction and regulatory compliance. This fits the category of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as major asset restructurings involving share issuance.
2016-11-24 Chinese
关于重大资产重组停牌进展公告
Capital/Financing Update Classification · 95% confidence The document is titled as an announcement regarding the progress of a major asset restructuring and the continuation of stock suspension (停牌进展公告). It references previous announcements about the same matter and details ongoing work related to the asset purchase transaction, including involvement of financial advisors, auditors, and legal counsel. The document does not contain financial statements or detailed financial data but rather updates on the status of the restructuring process and regulatory compliance. The document length is 2090 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Capital/Financing Update (CAP) since it relates to a significant financing transaction and restructuring progress.
2016-11-17 Chinese
关于重大资产重组停牌进展公告
Capital/Financing Update Classification · 95% confidence The document is a progress announcement regarding a major asset restructuring (重大资产重组停牌进展公告) by 嘉事堂药业股份有限公司. It details the ongoing status of the company's stock suspension due to the planned issuance of shares to purchase assets, mentions previous related announcements, and outlines the expected timeline and regulatory approvals needed. The document does not contain financial statements or detailed financial analysis but serves as an update on the status of the restructuring and stock suspension. It is not a full report but a regulatory announcement about the progress of a capital transaction. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short (2189 characters), and it is not merely announcing the publication of a report but providing substantive progress information on a capital restructuring event.
2016-11-10 Chinese
2016年第一次临时股东大会会议决议暨中小投资者表决结果公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions and voting results from the 2016 first extraordinary general meeting (临时股东大会) of 嘉事堂药业股份有限公司. It details the voting outcomes on various proposals, including issuance of asset-backed notes and credit applications, with specific vote counts and percentages. It also includes legal opinions confirming the validity of the meeting and resolutions. The document is not a full report but a formal announcement of voting results from a shareholder meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is relatively short (2422 characters), consistent with an announcement rather than a full report.
2016-11-03 Chinese
2016年第一次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2016 first extraordinary general meeting (EGM) of shareholders of 嘉事堂药业股份有限公司. It details the legality and compliance of the meeting's convening, attendance, voting procedures, and results. The document includes the law firm's certification of the meeting's validity and the voting outcomes on specific proposals. It is not a financial report, earnings release, or management discussion, but a legal opinion related to a shareholders' meeting. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal filing that does not fit other specific categories such as AGM Information or Declaration of Voting Results, since it is a legal opinion rather than the meeting materials or voting results announcement itself. The document length is under 5,000 characters, and it is a standalone legal opinion letter, not a report or announcement of a report publication.
2016-11-03 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.